Koit Biopharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 25-05-2024
- Paid Up Capital ₹ 0.10 M
as on 25-05-2024
- Company Age 4 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -33.22%
(FY 2022)
- Profit -19076.14%
(FY 2022)
- Ebitda -100.40%
(FY 2022)
- Net Worth -537.09%
(FY 2022)
- Total Assets 51.00%
(FY 2022)
About Koit Biopharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nidhi Kedar, Apoorva Mehta, and Devi Sonajhary serve as directors at the Company.
- CIN/LLPIN
U24239GJ2020PTC113446
- Company No.
113446
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Apr 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Koit Biopharma Private Limited offer?
Koit Biopharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Cardiovascular Drugs & Medication, Immunosuppressive Drugs, Hand Sanitizers & Personal Hygiene, Beauty Soap, Hair Growth Medicine, TB, Tumor & Cancer Drugs.
Who are the key members and board of directors at Koit Biopharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Apoorva Mehta  | Director | 18-Apr-2020 | Current |
| Nidhi Kedar | Director | 18-Apr-2020 | Current |
| Devi Sonajhary | Director | 18-Apr-2020 | Current |
Financial Performance of Koit Biopharma.
Koit Biopharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 33.22% decrease. The company also saw a substantial fall in profitability, with a 19076.14% decrease in profit. The company's net worth observed a substantial decline by a decrease of 537.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Koit Biopharma?
Unlock access to Koit Biopharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Koit Biopharma?
Unlock and access historical data on people associated with Koit Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Koit Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Koit Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
